Ovarian cancer stem cells: elusive targets for chemotherapy (Q38013671)

27 August 2017

title

Ovarian cancer stem cells: elusive targets for chemotherapy (English)

1 reference

27 August 2017

1 reference

1 reference

neoplastic stem cells

1 reference

Achuta Kumar Guddati

1

1 reference

27 August 2017

publication date

26 May 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

29

1 reference

27 August 2017

issue

5

1 reference

27 August 2017

page(s)

3400-3408

1 reference

https://scigraph.springernature.com/pub.10.1007/s12032-012-0252-6

27 August 2017

exact match

0 references

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Management of recurrent ovarian carcinoma: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Ovarian cancer pathogenesis: a model in evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

The cell of origin of ovarian epithelial tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Possible role of ovarian epithelial inflammation in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Pathologic findings in prophylactic oophorectomy specimens in high-risk women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Human fallopian tube: a new source of multipotent adult mesenchymal stem cells discarded in surgical procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Identification of surface markers for prospective isolation of human endometrial stromal colony-forming cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Evaluating the progenitor cells of ovarian cancer: analysis of current animal models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Oocyte formation by mitotically active germ cells purified from ovaries of reproductive-age women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Normal ovarian surface epithelial label-retaining cells exhibit stem/progenitor cell characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Parthenogenetic embryo-like structures in the human ovarian surface epithelium cell culture in postmenopausal women with no naturally present follicles and oocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Establishment of clonal colony-forming assay for propagation of pancreatic cancer cells with stem cell properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Assay of human stem cells by repopulation of NOD/SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Purification of hematopoietic stem cells using the side population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Erratum to: Functional and molecular characterisation of mammary side population cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Prospective identification of tumorigenic breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Identification of label-retaining cells in nasopharyngeal epithelia and nasopharyngeal carcinoma tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

The hepatic stem cell niche: identification by label-retaining cell assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Characterization of benign and malignant prostate epithelial Hoechst 33342 side populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Characterization of the Hoechst 33342 side population from normal and malignant human renal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Usefulness of PKH fluorescent labelling to study leukemic cell proliferation with various cytostatic drugs or acetyl tetrapeptide--AcSDKP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Hematopoietic stem cells exhibit a specific ABC transporter gene expression profile clearly distinct from other stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Measurement of multiple drug resistance transporter activity in putative cancer stem/progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Identification of cancer stem-like side population cells in ovarian cancer cell line OVCAR-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Isolation and characterization of stem-like cells from a human ovarian cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Clinical significance of side population in ovarian cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Mapping stem cell activities in the feather follicle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

CD133-expressing stem cells associated with ovarian metastases establish an endothelial hierarchy and contribute to tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Nonadhesive culture system as a model of rapid sphere formation with cancer stem cell properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Intraperitoneal chemotherapy in the management of patients with advanced epithelial ovarian cancer: a critical review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

A phase 3 trial of bevacizumab in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Stem cell pathways contribute to clinical chemoresistance in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Intratumoral heterogeneity in the self-renewal and tumorigenic differentiation of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

The epithelial-mesenchymal transition generates cells with properties of stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Nuclear-mitochondrial genomic profiling reveals a pattern of evolution in epithelial ovarian tumor stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Expression of CD133-1 and CD133-2 in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Identification and characterization of ovarian cancer-initiating cells from primary human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

CD133 expression associated with poor prognosis in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

CD133, a novel marker for human prostatic epithelial stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Identification of human brain tumour initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunocytochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies of the NCIC Clinical Trials Group (NCIC CTG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Intensive expression of Bmi-1 is a new independent predictor of poor outcome in patients with ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0252-6

Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia

21 January 2018

1 reference

12 December 2020

Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy

1 reference

12 December 2020

CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV

1 reference

12 December 2020

Functional and molecular characterisation of mammary side population cells

1 reference

12 December 2020

Stem-like cells in bladder cancer cell lines with differential sensitivity to cisplatin.

1 reference

12 December 2020

Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer

1 reference

12 December 2020

XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells

1 reference

12 December 2020

Atypical Epithelial Proliferation in Fallopian Tubes in Prophylactic Salpingo-oophorectomy Specimens from BRCA1 and BRCA2 Germline Mutation Carriers

1 reference

12 December 2020

ALDH1 expression correlates with favorable prognosis in ovarian cancers

1 reference

12 December 2020

CD133 expression defines a tumor initiating cell population in primary human ovarian cancer

1 reference

12 December 2020

Cancer stem-like cells contribute to cisplatin resistance and progression in bladder cancer

1 reference

12 December 2020

HER-2/neu amplification and overexpression in endometrial carcinoma.

1 reference

12 December 2020

Delay in diagnosis of epithelial ovarian cancer

1 reference

12 December 2020

Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway

1 reference

12 December 2020

Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients.

1 reference

12 December 2020

Expression of MDR1 in epithelial ovarian cancer and its association with disease progression

1 reference

12 December 2020

Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma

1 reference

12 December 2020

Effects of the combination of RAD001 and docetaxel on breast cancer stem cells

1 reference

12 December 2020

Demonstration of multipotent stem cells in the adult human endometrium by in vitro chondrogenesis

1 reference

12 December 2020

Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer

1 reference

12 December 2020

p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells.

1 reference

12 December 2020

P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer

1 reference

12 December 2020

Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed

1 reference

12 December 2020

Pathology and classification of ovarian tumors

1 reference

12 December 2020

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

1 reference

12 December 2020

10.1007/S12032-012-0252-6

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1020094817

0 references

1 reference